Immupharma Share Discussion Threads

[bbluesky] 03/2/2021 19:02

I would not recommend looking on a daily basis.

[adelwire2] 03/2/2021 15:25

Any hope for this share?????

[ascov] 02/2/2021 18:39

Now let's get this right... Is it a better bet to believe the Company and fall on the side that they are not so completely stupid as Professionals as to get the dose wrong ? OR... should I believe some bloke who is anonymous and says he knows more than anyone else about something he cannot possibly have information on.....
Hmmm...Tricky one...I think I'll ignore the fantasist..

[albert arthur] 02/2/2021 17:44

Ignore Noby. He talks and follows himself on circa 300 accounts. He's gonna get a short toasting.

[nobbygnome] 02/2/2021 09:03

>> not knowing

It's an injection. The problem is that the management are ignoring the science they generated which clearly shows it can't work at the doses used IMHO.

[brad44] 02/2/2021 08:52

just ignore the nobhead on wall st. he thinks he is the worlds best at everything...deluded prat

[notknowing] 02/2/2021 08:38

But that can be tweaked right? Take two pills instead of one!

Anyway, the chart looks good, so suspect there will be some news imminently which attracts the herd.

[nobbygnome] 02/2/2021 08:34

LOL. In short, no! My strong opinion is that it won't work. They are using a dose which is far too low.

[notknowing] 02/2/2021 08:32

But as a PHD in immunology....does the product have legs?

[nobbygnome] 02/2/2021 08:28

No, most definitely not. I have a few because I bought back in September as a pint because of the alleged SPA approval. Here we are 5 months later with no further news.

My views on the management team here are well known so I won't repeat them.....

[notknowing] 02/2/2021 08:24

I have just bought a few of these based on the chart pattern. Looks set to rocket.

Are you a fan of IMM Nobby?

[waterloo01] 01/2/2021 21:56

lol Rinse and repeat.

[nobbygnome] 01/2/2021 21:48

And I have detailed knowledge of Lupuzor from my time in the industry...

[nobbygnome] 01/2/2021 21:47

Interesting word spamming....

Retired very early and now trade the markets. My two big recent winners are SNG and TLY! Yes STX is currently my dog....but will come back strongly when the US strategy is finally sorted.

[albert arthur] 01/2/2021 21:42

Says noby, who's been on ADVFN since year 2000 and still spamming. You must have been very successful to still be here.

[nobbygnome] 01/2/2021 21:40

Talk about mug punters....

[albert arthur] 01/2/2021 21:39

?Welcome to the Immupharma thread. An SPA application for the lead drug Lupuzor, which hopes to enter its second Phase 3 later this year (2020) is before the FDA with results expected imminently. In addition there is an exciting portfolio.Lupus is a disease where the immune system goes wrong. Your body thinks that it is ill when it is not and the overactive immune system attacks healthy tissue. Many drugs have failed lupus trials because they try to suppress the immune system. The problem with this approach is that if you suppress the immune system too little, then the lupus not go away. If you suppress the immune system too much, you weaken the body to other illnesses.Immupharma's drug Lupuzor is different. It has a novel mechanism of action aimed at modulating the body's immune system (rather than suppressing it) so it does not attack healthy cells, without causing adverse side effects. See the video presentations of Prof Sylvaine Muller at hTTps://player.vimeo.com/video/170358317 and hTTps://vimeo.com/151506805. It also has the potential to halt the progression of the disease in a substantial proportion of patients.The potential clinical market available to Lupuzor is estimated to be in multiple $bns (billions) per year. See the 2019 Annual Report and the below presentation from Immupharma:hTTps://www.immupharma.co.uk/wp-content/uploads/2020/05/ImmuPharma-Annual-Report-31.12.2019-FINAL.pdfhTTps://www.immupharma.co.uk/wp-content/uploads/2020/04/IMM-Corporate-Presentation-website-7-April-2020-FINAL-FINAL.pdfPlease see the information in the scroll box, below the charts, for much more information about Immupharma and Lupuzor.

[albert arthur] 01/2/2021 21:35

It’s a lupus drug, on the brink on FDA SPA. No reason it won’t get it. When it lands. It’ll do 1-200%. On this cap easily.

[nobbygnome] 01/2/2021 20:37

It's got absolutely zero chance of being a drug to treat Covid but Tim et al have hyped it as such. I presume there are some mug punters who believe it....

[bendaddy] 01/2/2021 18:46

Of course. I realise that. I thought you meant that Immupharma has nothing to do with Covid after Nobbygnome had questioned why their share price is stagnant compared to 'other Covid related biotechs'

[albert arthur] 01/2/2021 18:26

Cytokine storm and ARDS, is unrelated to the pending FDA for the SPA of the Lupus drug... TILS have a IL6 MaB which treats Cytokine Storm, pending FDA IND, nothing to do with this thread.

[bendaddy] 30/1/2021 22:54

Yes it does have something to do with Covid. Severe Covid patients have an autoimmune-like immune system over-reaction with an unregulated cytokine storm and associated inflammation at many ACE2 inhibitor sites and they produce autoantibodies including towards interferons. The interplay between autophagy, viral replication and the immune response is important. So because of its unique mechanism of action Immupharma are looking at any potential pharmacological effects of the P140 peptide - probably in vitro and cell studies. With Ureka they are also looking at anti-infective peptides including an antiviral for Covid.

[albert arthur] 30/1/2021 18:47

Also, this has "Nothing to do with covid"

[albert arthur] 30/1/2021 18:46

It will come.. 60 days next week. Patience will bring....